Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
2018 2
2019 3
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Kastritis E, et al. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. N Engl J Med. 2021. PMID: 34192431 Clinical Trial.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality -cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM).
Garnica M, Crusoe EQ, Ribeiro G, Bittencourt R, Magalhães RJP, Zanella KR, Hallack Neto AE, Lima JS, Solo CB, Souza EG, Fernandes AM, Maiolino A, Hungria V. Garnica M, et al. Among authors: zanella kr. Hematol Transfus Cell Ther. 2023 Sep 13:S2531-1379(23)00171-2. doi: 10.1016/j.htct.2023.08.002. Online ahead of print. Hematol Transfus Cell Ther. 2023. PMID: 37718131 Free article.
Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation.
Crusoe EQ, Higashi F, Martinez G, Bittencourt R, Pinto Neto JV, Sousa L, Santucci R, Magalhães RJP, Colli G, Nunes RFM, Ribeiro G, Nicacio J, Zanella KR, Kutner JM, Magalhaes A, Leao D, Hallack Neto AE, Braga W, Souza EG, Guimaraes AJAM, Durigon GS, Laks D, Maiolino A, Hungria VTM; GBRAM- (GRUPO BRASILEIRO DE MIELOMA). Crusoe EQ, et al. Among authors: zanella kr. Hematol Transfus Cell Ther. 2020 Apr-Jun;42(2):118-124. doi: 10.1016/j.htct.2019.05.004. Epub 2019 Aug 12. Hematol Transfus Cell Ther. 2020. PMID: 31537476 Free PMC article.